This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from three United Kingdom institutions in Sutton, London, and Manchester evaluated the vaccine-specific antibody persistence and immunogenicity of five childhood vaccines (MMR, tetanus toxoid, IPV, Hib conjugate, and meningococcus C [MCC]) after completion of chemotherapy for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Fifty-nine previously vaccinated children ages 1–18 years who had completed treatment for ALL or AML at least six months earlier were enrolled over a two-year period. Patients were revaccinated with one dose each of DTaP, IPV, Hib, Measles (administered as MMR), and MCC. Blood samples for serologic testing were obtained on the day of vaccination, at two to four weeks, and one year later. For each of the five vaccines, there was a significant rise in the antibody level after revaccination. …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
